What people changed

What people changed.

Four people, anonymised. We changed the names and blurred the details to protect them. Everything else is real: the variants we found, what they mean, and the choices each person made to live a little longer, and a little better, afterwards.

With the explicit consent of each person for the publication of the abstracted account below.

Cardiovascular

The heart she planned for at forty-five, not sixty

She turned a family worry into a plan she could act on at forty-five instead of sixty. She took the Lp(a) finding to her physician, who ordered the one-time blood test her standard panels had never included, putting a real number where there had only been her father's history. Knowing diet may carry more weight for an e4 carrier, she shifted the everyday fats in her cooking, a change small enough to keep and early enough to compound. And together with her physician she settled on a yearly lipid check, years before most people start, so the heart she was protecting would be watched on her schedule, not her family's.

The person

A woman in her mid-forties, fit and asymptomatic, with a father who had a bypass at sixty and a quiet worry she had been carrying since. She did not want to wait for a bad cholesterol panel to tell her something her family already had.

What they asked

Whether the heart history on her father's side was something she carried too, and what she could do about it now, in her forties, rather than discover it the way he did in his sixties. She wanted the cardiovascular and lipid areas read closely, in plain language, with the lineage set aside for another day.

What was found

APOE, e3/e4 genotype (rs429358, rs7412)One copy of the e4 form of APOE, a gene that shapes how the body handles dietary fat and cholesterol. In e4 carriers, LDL cholesterol tends to run a little higher and often responds more sharply to a diet heavy in saturated fat. Read here purely as a lipid and cardiovascular signal, and nothing more, it simply means her cholesterol is worth watching a little earlier, and that what she eats may carry more weight for her than for most. It is a tendency, not a verdict, and not a statement about anything beyond her lipids.
9p21, rs10757278 risk alleleThe most replicated common variant for coronary artery disease, carried by a large share of the population. A risk allele here modestly raises lifetime odds of coronary disease, independent of cholesterol. It changes nothing she feels today; it is simply a reason to begin everyday prevention in her forties rather than her sixties, which is the whole point of knowing it now.
LPA, rs10455872 G alleleA variant linked to higher lipoprotein(a), or Lp(a), an inherited cholesterol-like particle that a standard lipid panel does not measure and that diet and exercise barely move. This marker mainly flags raised Lp(a) in people of European ancestry, and it captures only part of the picture, so it cannot rule the trait in or out on its own. That is exactly why it is the finding of clinical consequence here: it points toward a simple one-time Lp(a) blood test, a conversation best had with her physician, so a number her family history only hinted at is finally measured rather than assumed, whatever her genotype suggests.

Pharmacogenomics

One document, before the fourth prescription

He brought his analysis to his physician, and most of it was settled in one conversation. The statin was swapped for one that clears differently, and the muscle aches went away. The new PPI was started at the lower dose. The warfarin note now sits in his chart, useful years before anyone needs it.

The person

A man in his mid-fifties, on three regular medications including a statin that did not sit well with him. He was about to start a fourth.

What they asked

How his body handles medication, first and foremost. He wanted one document to bring to his physician that captured everything worth knowing before another prescription was added.

What was found

SLCO1B1, reduced transporter functionThe liver protein that clears statins from the blood works at reduced capacity, so statins build up more. That fits the muscle aches he reported on simvastatin, and points to a statin that relies less on this pathway, at his physician's discretion.
CYP2C19, intermediate metaboliserThe fourth medication being considered was a PPI (a common acid-reducing drug). He breaks it down more slowly than average, so it lingers a little longer. No reason to avoid it, just a reason to start at the lower dose and reassess.
CYP2C9 + VKORC1, combined sensitivityIf the blood thinner warfarin is ever prescribed, this pair of variants predicts he would be unusually sensitive to standard doses. Nothing to do today; the note travels with him to any future conversation about blood thinners.

Healthspan

The body she will live in at seventy, planned now

She treated bone and vitamin D as a long, low-effort project rather than a worry. She added a once-a-year vitamin D level to her routine bloodwork so she could see her own number across seasons instead of guessing, and shared the GC and VDR notes with her physician to decide together whether a modest, steady vitamin D habit made sense for her, especially through winter. Knowing her calcium came more easily from non-dairy sources, she leaned into those on purpose and kept doing the load-bearing walking and strength work she already enjoyed, now understanding it was the part of her routine her habits paid back the most. Nothing alarming, just a quieter confidence about the decades ahead.

The person

A woman in her late forties, well, active, with no fractures and no diagnosis. She had started noticing the conversations around her shift toward aging, and she wanted to spend the next few decades strong rather than cautious. Her question was about the body she would be living in at seventy, planned for now.

What they asked

Which parts of staying strong and energetic past fifty are worth her deliberate attention, and which she could simply let be. She did not want a verdict on her future. She wanted to know where her own biology rewards good habits the most, so the effort she was already willing to make would actually compound.

What was found

GC rs2282679 (vitamin D binding protein)A common variant in the protein that carries vitamin D through the blood. It tends to track with a slightly lower amount of vitamin D in circulation, and that gap usually widens in the darker, lower-sun months. It does not mean a deficiency. It simply means her body may hold a thinner margin than average, which is useful to know rather than to fear, and easy to keep an eye on with a seasonal blood level.
VDR FokI rs2228570 (vitamin D receptor)A well-studied variant in how cells read the vitamin D signal that supports calcium handling and bone upkeep. Her version sits in the more-responsive range. The link between this single variant and actual bone density is modest and varies between populations, so it is not a promise of stronger bones. It is one more reason that keeping vitamin D and calcium steadily available, rather than relying on a single good day, is effort well spent for her.
LCT / MCM6 rs4988235 (lactase persistence)This marker reads whether the dairy-digesting gene stays switched on into adulthood, as established in people of European ancestry. It helps explain her appetite for, or quiet avoidance of, dairy, one of the simplest dietary routes to calcium. In other ancestries, lactase persistence can run through different variants this test does not capture, so for some people dairy tolerance is better judged by how they actually feel than by this single result. Either way it is a dial on how she gets calcium, not a problem to solve.

Inheritance

A plain-language picture before they started a family

Two things changed for them. They stopped worrying about cystic fibrosis, the question they had asked first, carrying one less unknown into a pregnancy. And they noted to mention the Factor V finding to her OB at the booking visit, putting attention where it matters before it matters. The lineage they now talk about most; it has become part of how they think about the family they are starting.

The person

A couple in their early thirties, hoping for a child within two years. Both reasonably fit, with no family history they knew of.

What they asked

What they each carry, and what that could mean for a future child, read across both of them at once. They were not looking for clinical answers, just a plain-language picture before they started a family.

What was found

CFTR, ΔF508 heterozygote (one of two)She carries one copy of the most common cystic fibrosis variant; he carries none. Because it takes two copies to cause the condition, a future child has roughly a one in two chance of being a healthy carrier and effectively no chance of being affected, based on the data we hold.
Factor V Leiden, both heterozygousBoth partners carry one copy of a variant linked to blood clotting. No treatment is needed now. It is simply worth mentioning to her obstetrician at the first pregnancy visit, since pregnancy measurably raises clot risk in carriers.
Mitochondrial, haplogroup K1aHer maternal line traces through Ashkenazi Jewish Europe and, earlier, across the Near East. Set alongside his paternal line (Y-haplogroup R1b-M269), these are the two ancestral lines a future child would carry forward.

A note

None of the above is medical advice.

An analysis is informational and educational, not clinical. It is written to be considered and brought to a physician where the variants imply a clinical conversation. The outcomes above describe what these people chose to do after speaking with their own healthcare professionals. Your analysis, and your decisions, will be your own.

Your own analysis

Join the people who decided to age by design.

The accounts above sit next to each other not because their authors do, but because the same scientist sat with each one, and turned what was written in their DNA into a few choices worth living by. Your conversation would begin the same way.

Request your consultation →